Latest News

High adverse events with TB prevention in HIV-infected pregnant women


 

FROM CROI 2018


All women and their infants received the local standard of care for HIV. The investigators performed intensified TB case finding by using the WHO symptoms screening and exam, monitoring of signs and symptoms, conducting liver function tests, and screening for peripheral neuropathy.

“We had higher than expected adverse events in the study, but there was no statistical difference between arms,” she said.

In an intention-to-treat analysis, the rate of first maternal treatment-related grade 3 or greater adverse event or permanent drug discontinuation caused by toxicity (the primary endpoint) was 15.5% in the immediate IPT arm and 15.2% in the delayed IPT arm, a nonsignificant difference. The immediate therapy arm approached but did not quite reach the prespecified boundary of noninferiority, Dr. Gupta noted.

The per-protocol analysis of the primary endpoint was similar, at 17.6% vs. 17.8%, respectively.

Pages

Recommended Reading

FDA approves new combination drug for HIV patients
MDedge Family Medicine
Gut-homing protein predicts HIV-acquisition, disease progression in women
MDedge Family Medicine
Inflammatory markers predict vaccine response in HCV, HIV
MDedge Family Medicine
VIDEO: The return of Kaposi’s sarcoma
MDedge Family Medicine
Bloating. Flatulence. Think SIBO
MDedge Family Medicine
One-month TB-prevention regimen effective in HIV+ individuals
MDedge Family Medicine
Hair tracks HIV antiretroviral adherence
MDedge Family Medicine
FDA approves new treatment for multidrug-resistant HIV
MDedge Family Medicine
Looking to increase PrEP uptake
MDedge Family Medicine
Efavirenz-based ART may hamper vaginal ring contraception
MDedge Family Medicine